Literature DB >> 9694609

Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status.

R Pratap1, S Shousha.   

Abstract

There is evidence to suggest that breast carcinoma in young women behaves in a more aggressive manner than in older women. As positive immunostaining for p53 has also been associated with increased tumour aggressiveness, this study was aimed at finding out whether patients under the age of 50 years have a higher prevalence of p53 positivity in their tumours. The inter-relationships between age, p53, tumour grade, and axillary lymph node status were also investigated. Two hundred and twenty nine invasive carcinomas were studied. One hundred and eight patients were under the age of 50, and 121 were at or above that age. The specific p53 monoclonal antibody DO7 and the avidin-biotin complex immunoperoxidase technique were used. Fifty seven tumours (25 %) showed variable degrees of p53 positivity. The incidence of positivity was slightly higher in women under the age of 50 as compared with those at or above that age (29% (31/108) vs. 21% (26/121), respectively), but the difference was not statistically significant (p < 0.05). On the other hand, in invasive ductal carcinoma (191 cases), p53 positivity was significantly related to high tumour grade (7% in grade I [1/14], 19% in grade II [20/105], and 43% in grade III [31/72]; p < 0.0001 [I-II vs III]). p53 positivity was also significantly related to the presence of extensive (more than three) axillary lymph node metastases (p53 positivity being 22% in node negative tumours [40/178], 18% in tumours with three or less positive nodes [6/33], and 61% in tumours with more than 3 positive nodes [11/18]; p = 0.0033 [second vs third group]). Both features were also significantly more common in the younger age group. The results suggest that the slightly higher incidence of p53 positivity seen in tumours from younger patients, is probably related to the significantly higher incidence of grade III tumours in these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694609     DOI: 10.1023/a:1005993220824

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study.

Authors:  I F O'Connor; M V Shembekar; S Shousha
Journal:  J Clin Pathol       Date:  1998-12       Impact factor: 3.411

2.  Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.

Authors:  Ezzeldin M Ibrahim; Adnan A Ezzat; Mohammed M Rahal; Madras M Raja; Dahish S Ajarim
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.

Authors:  Beth O Van Emburgh; Jennifer J Hu; Edward A Levine; Libyadda J Mosley; Nancy D Perrier; Rita I Freimanis; Glenn O Allen; Peter Rubin; Gary B Sherrill; Cindy S Shaw; Lisa A Carey; Lynda R Sawyer; Mark Steven Miller
Journal:  Oncol Rep       Date:  2008-05       Impact factor: 3.906

4.  Breast cancer in Chinese women younger than age 40: are they different from their older counterparts?

Authors:  Ava Kwong; Polly Cheung; Stephanie Chan; Silvia Lau
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

5.  Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.

Authors:  Manal F Ismail; Magdy Sayed Aly; Hussein M Khaled; Hanaa M Mohamed
Journal:  Ger Med Sci       Date:  2009-05-06

6.  Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.

Authors:  Qiong Yu; Yan Li; Kun Mu; Zhishuang Li; Qingyong Meng; Xiaojuan Wu; Yan Wang; Li Li
Journal:  Diagn Pathol       Date:  2014-03-25       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.